Melatonin
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Melatonin |
| FDA Approval | No |
| Used for | Jet lag, insomnia, various types of cancer including Glioblastoma Multiforme (GBM) |
| Clinical Trial Phase | Phase-2 and Phase-3 trials |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | No known toxic side effects |
| OS without | Not specified |
| OS with | Improved survival in some cancer treatments |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 1 |
| Toxicity Explanation | Melatonin is considered to have a low toxicity level, with no known toxic side effects. It is generally regarded as safe for use in the dosages typically administered for both sleep disorders and experimental cancer treatment protocols. |
Notes: Melatonin is a hormone that regulates the body's diurnal rhythm and is used for the treatment of sleep disorders. In cancer treatment, it's hypothesized to boost the immune system, inhibit angiogenesis, and have direct cytotoxic effects on certain cancer cells. Clinical research, primarily in Italy, has explored its use alone or in combination with chemotherapy or immunotherapy, showing potential for increasing survival rates and reducing chemotherapy toxicity.
Links: * [Relevant study or information link]
From Ben Williams Book: Not specified
Loading comments...
